A Hipparcos study of the Hyades open cluster: Improved colour-absolute magnitude and Hertzsprung-Russell diagrams

Hipparcos parallaxes fix distances to individual stars in the Hyades cluster with an accuracy of 6%. We use the Hipparcos (and Tycho-2) proper motions, which have a larger relative precision than the trigonometric parallaxes, to derive ~3 times more precise distance estimates, by assuming that all members share the same space motion. The improved parallaxes as a set are statistically consistent with the Hipparcos parallaxes. The new parallaxes confirm that the Hipparcos measurements are correlated on small angular scales, consistent with the limits specified in the Hipparcos Catalogue, though with significantly smaller `amplitudes' than claimed by Narayanan & Gould. The colour-absolute magnitude diagram of the cluster based on the new paral- laxes shows a well-defined main sequence with two gaps/turn-offs. These features provide the first direct observational support of Boehm-Vitense's prediction that (the onset of) surface convection in stars affects their B-V colours. We present and discuss the theoretical HRD for an objectively defined set of 88 high-fidelity members of the cluster as well as the delta Scuti star theta^2 Tau, the giants delta^1, theta^1, epsilon, and gamma Tau, and the white dwarfs V471 Tau and HD 27483 (all of which are also members). The precision with which the new parallaxes place individual Hyades members in the Hertz- sprung-Russell diagram is limited by (systematic) uncertainties related to the transformations from observed colours and absolute magnitudes to effective temperatures and luminosities. The new parallaxes provide stringent constraints on the calibration of such transformations when combined with theoretical stellar evolutionary modelling, tailored to the chemical composition and age of the Hyades, over the large stellar mass range probed by Hipparcos.Comment: 41 pages, 20 PostScript figures (24 files), LaTeX using lscape.sty and psfig.sty; accepted for publication in Astronomy & Astrophysics; data in electronic format may be obtained from the author

Adenine base editing efficiently restores the function of Fanconi anemia hematopoietic stem and progenitor cells

Fanconi Anemia (FA) is a debilitating genetic disorder with a wide range of severe symptoms including bone marrow failure and predisposition to cancer. CRISPR-Cas genome editing manipulates genotypes by harnessing DNA repair and has been proposed as a potential cure for FA. But FA is caused by deficiencies in DNA repair itself, preventing the use of editing strategies such as homology directed repair. Recently developed base editing (BE) systems do not rely on double stranded DNA breaks and might be used to target mutations in FA genes, but this remains to be tested. Here we develop a proof of concept therapeutic base editing strategy to address two of the most prevalent FANCA mutations in patient hematopoietic stem and progenitor cells. We find that optimizing adenine base editor construct, vector type, guide RNA format, and delivery conditions leads to very effective genetic modification in multiple FA patient backgrounds. Optimized base editing restored FANCA expression, molecular function of the FA pathway, and phenotypic resistance to crosslinking agents. ABE8e mediated editing in primary hematopoietic stem and progenitor cells from FA patients was both genotypically effective and restored FA pathway function, indicating the potential of base editing strategies for future clinical application in FA.ISSN:2041-172

An Individual Patient Data Meta-Analysis on Characteristics and Outcome of Patients with Papillary Glioneuronal Tumor, Rosette Glioneuronal Tumor with Neuropil-Like Islands and Rosette Forming Glioneuronal Tumor of the Fourth Ventricle

<div><p>Background and Purpose</p><p>In 2007, the WHO classification of brain tumors was extended by three new entities of glioneuronal tumors: papillary glioneuronal tumor (PGNT), rosette-forming glioneuronal tumor of the fourth ventricle (RGNT) and glioneuronal tumor with neuropil-like islands (GNTNI). Focusing on clinical characteristics and outcome, the authors performed a comprehensive individual patient data (IPD) meta-analysis of the cases reported in literature until December 2012.</p><p>Methods</p><p>PubMed, Embase and Web of Science were searched for peer-reviewed articles reporting on PGNT, RGNT, and GNTNI using predefined keywords.</p><p>Results</p><p>95 publications reported on 182 patients (PGNT, 71; GNTNI, 26; RGNT, 85). Median age at diagnosis was 23 years (range 4–75) for PGNT, 27 years (range 6–79) for RGNT, and 40 years (range 2–65) for GNTNI. Ninety-seven percent of PGNT and 69% of GNTNI were located in the supratentorial region, 23% of GNTNI were in the spinal cord, and 80% of RGNT were localized in the posterior fossa. Complete resection was reported in 52 PGNT (73%), 36 RGNT (42%), and 7 GNTNI (27%) patients. Eight PGNT, 3 RGNT, and 12 GNTNI patients were treated with chemo- and/or radiotherapy as the primary postoperative treatment. Follow-up data were available for 132 cases. After a median follow-up time of 1.5 years (range 0.2–25) across all patients, 1.5-year progression-free survival rates were 52±12% for GNTNI, 86±5% for PGNT, and 100% for RGNT. The 1.5-year overall-survival were 95±5%, 98±2%, and 100%, respectively.</p><p>Conclusions</p><p>The clinical understanding of the three new entities of glioneuronal tumors, PGNT, RGNT and GNTNI, is currently emerging. The present meta-analysis will hopefully contribute to a delineation of their diagnostic, therapeutic, and prognostic profiles. However, the available data do not provide a solid basis to define the optimum treatment approach. Hence, a central register should be established.</p></div

Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen : Acute toxicity in pediatric high-grade glioma patients

As the efficacy of all pediatric high-grade glioma (HGG) treatments is similar and still disappointing, it is essential to also investigate the toxicity of available treatments

Clinical Characteristics of ….

<p>Clinical Characteristics of ….</p

Kaplan-Meier Plot OS.

<p>Kaplan-Meier Plot OS.</p

Limitation of this study - non-English articles.

<p>Note: n/s – not specified; y/n – yes/no.</p>a<p>Provided by title of the article or abstract if available.</p